Abstract 295P
Background
During the last two decades, health-related quality of life (QoL) measurements have been an important issue in understanding the difficulties perceived in many diseases. It is important to assess the health-related quality of life to know the extent of diseases and conditions affecting individual’s general well-being. Studies have shown the effect various determinants of Quality of Life (QoL) in lung cancer patients. This study was done to assess the QoL in individuals with non- small cell lung cancer undergoing palliative care.
Methods
Materials and Method: Data on QoL were collected using a modified MOS-SF form-32. The study was done in 27 individuals before and after providing supportive or palliative care. A random mixed linear model was used to assess impact of palliative care on Quality of Life with Physical Health Summary score and Mental Health Summary score as main outcomes. All the possible confounding factors were controlled in the study.
Results
When values were compared before and after giving palliative care the Physical Health Summary score decreased considerably. (diff=-2.12; 95% CI: [-4.08, -0.63]) with small to medium effect sizes. The PHS Score remained lower after being on palliative care for more than 2 years (diff=-5.86; 95% CI: [-7.89, -3.63]).]). The Mental Health summary score didn’t change significantly after giving palliative care (diff=-5.86; 95% CI: [-7.89, -3.63]). The Mental Health summary score was higher after HAART for more than 5 years when compared prior to infection.
Conclusions
Quality of life is an important determinant in the course of lung cancer. Palliative or supportive care can play a vital role in improving the quality of life in patients with lung cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
67TiP - HER2CLIMB-02: A randomized, double-blind, phase III study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer
Presenter: Norikazu Masuda
Session: e-Poster Display Session
68TiP - KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) + olaparib (ola) vs pembro + chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC
Presenter: Shigehira Saji
Session: e-Poster Display Session
69TiP - MADELINE Asia: A mobile app-based prospective observational study of patient reported outcomes in advanced breast cancer in Asia
Presenter: Anna Tai
Session: e-Poster Display Session
113TiP - Prospective observational study monitoring circulating tumour DNA in resectable colorectal cancer patients undergoing radical surgery: GALAXY study in CIRCULATE-Japan
Presenter: Hiroki Yukami
Session: e-Poster Display Session
195TiP - GLOW: Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin18.2⁺/HER2⁻ advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
Presenter: Rui-Hua Xu
Session: e-Poster Display Session
196TiP - Perioperative sintilimab in combination with concurrent chemoradiotherapy for patients with locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma
Presenter: Jia Wei
Session: e-Poster Display Session
197TiP - A randomized, double-blind, phase III study of pembrolizumab plus chemotherapy as first-line therapy in patients with HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859
Presenter: Shukui Qin
Session: e-Poster Display Session
198TiP - SPOTLIGHT: Phase III study of zolbetuximab + mFOLFOX6 versus placebo + mFOLFOX6 in first-line Claudin18.2⁺/HER2⁻ advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
Presenter: Kohei Shitara
Session: e-Poster Display Session
233TiP - Pembrolizumab (pembro) or placebo added to docetaxel and prednisone/prednisolone for metastatic castration-resistant prostate cancer (mCRPC) previously treated with next-generation hormonal agents (NHAs): KEYNOTE-921 phase III study
Presenter: Daniel Petrylak
Session: e-Poster Display Session
254TiP - ENGOT-cx11/KEYNOTE-A18: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab With Chemoradiotherapy in Patients With High-Risk Locally Advanced Cervical Cancer
Presenter: Domenica Lorusso
Session: e-Poster Display Session